Impact of early administration of empagliflozin in patients with acute decompensated heart failure on medium-term prognosis (3 and 6 months)
Abstract
Aim.
To evaluate the impact of early administration of empagliflozin — from the first day of treatment of acute decompensated heart failure (ADHF) on outcomes at 3 and 6 months.
Material and methods.
The study included 92 patients admitted to the hospital with ADHF without hemodynamic instability. On the 1st day of hospitalisation, patients were included in the study and were randomized to receive empagliflozin at a daily dose of 10 and 25 mg (in case of ineffective glycemic control for patients with type 2 diabetes mellitus) into two equal groups. The patients in the comparison group received treatment without gliflozines during the hospital period of the study, however, upon discharge from the hospital, empagliflozin or dapagliflozin was recommended along with other prescriptions, while 8 patients started taking this class of drug.: 7 — within 3 months after discharge from the hospital, 1 — during the 3rd — 6th month of the study. Data on the development of adverse cardiovascular events and surgical interventions for cardiovascular diseases, as well as side effects and adverse events associated with empagliflozin therapy were collected from all participants at each stage of inpatient and outpatient follow-up (3 and 6 months after discharge from the hospital).
Results.
Of the 92 study participants, there were 18 (19,6%) deaths (all due to ADHF) and 9 (9,8%) nonfatal cardiovascular events over the 6-month period. Over the entire observation period, a lower number of all…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 92 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.